Business Context and Reporting Period
This Form 8-K is a current report filed by Enochian Biosciences Inc. (not Lunai Bioworks Inc.) on January 11, 2019, covering events occurring on January 7, 2018, and January 9, 2019. The filing addresses Item 5.02 regarding the appointment of a new Chief Financial Officer (CFO) and the termination of a prior consulting arrangement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation:
- Annual Salary: $200,000 for the new CFO.
- Target Bonus: 40% of annual salary.
- Equity Grant: 60,000 stock options and 15,000 shares of restricted stock.
Material Changes
The primary material change is the leadership transition in the finance function:
- Appointment: Luisa Puche was hired as full-time CFO effective January 7, 2018, to support the company's growth as an exchange-listed entity.
- Termination: On January 9, 2019, the company terminated the consulting agreement with Robert Wolfe, who served as part-time CFO, following Ms. Puche's appointment.
Outlook, Risks, and Management Commentary
Management commentary indicates the appointment of Ms. Puche is intended to support the company's growth as an exchange-listed company. The filing states there are no other arrangements or understandings regarding her appointment and no actual or proposed transactions requiring disclosure under Item 404(a) of Regulation S-K. No specific risks, contingencies, or unusual items are detailed in this report.
Investor Verification Checklist
- Verify the correct registrant name is Enochian Biosciences Inc., not Lunai Bioworks Inc.
- Confirm the vesting schedule for the 60,000 stock options and 15,000 restricted shares granted to the new CFO.
- Review the 2014 Equity Incentive Plan to understand the terms of the equity grants.
- Check subsequent filings for any financial performance updates following the CFO transition.